Ginkgo Bioworks Holdings 주식 (NYSE: DNA)

에 대한 최신 뉴스 Ginkgo Bioworks Holdings (NYSE:DNA) 주식

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Equities

News

Markets

ETFs

ACHR

ARKK

AVAV

BLDE

NTLA

TDOC

TSLA

VERV

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:TSLA)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.

아크 인베스트가 예상을 넘는 2분기 배송 실적에도 $3.25백만 규모 테슬라 주식 매도 추가

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

ARKW

COIN

ROKU

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:ROKU)와 코인베이스 글로벌(NASDAQ:COIN)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래

아크 인베스트는 로쿠 $730만의 주식을 매수, 비트코인 하락에 코인베이스 주식을 매각

ARCT

ARKQ

MKFG

NVDA

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:NVDA)와 로쿠(NASDAQ:ROKU)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.

아크 인베스트는 주가 반등 속에 엔비디아 주식에서 $430만 매도, 로쿠 주식을 매수

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

Jefferies analyst Roger Song maintains Kura Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>) with a Buy and lowers the price target from $32 to $28.

Price Target

Analyst Ratings

KURA

Jefferies Maintains Buy on Kura Oncology, Lowers Price Target to $28

Jefferies analyst Brent Thill maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $145 to $180.

SNOW

Jefferies Maintains Buy on Snowflake, Raises Price Target to $180

Contracts

Verizon Business Secures 5-Year Agreement With USDA Valued At Over $21M In First Year

Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>, JFBRW))), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that it has entered into a patent licensing agreement (the "Licensing Agreement"), with Xiamen Fast Power Co., Ltd. ("Xiamen"), a Chinese company specializing in advanced photovoltaic technology. This Licensing Agreement grants Jeffs' Brands the right to use the registered patent number 6345668 owned by Xiamen, which covers innovative waterproof photovoltaic board technology, for a period of three years in exchange for royalty payments.
The Licensing Agreement marks a significant milestone for Jeffs' Brands, enabling the Company to diversify its product offerings and enhance its e-commerce portfolio on the Amazon Marketplace. Pursuant to the agreement, Jeffs' Brands will receive an exclusive right to market and sell the patented technology solely through Amazon, without geographical restrictions, aiming to target a global customer base.
Under the terms of the Licensing Agreement, Jeffs' Brands will pay royalties to Xiamen on a quarterly basis, equal to 15% of the net cash flow profit generated from sales made using the patented technology on the Amazon Marketplace.

JFBR

Jeffs' Brands Enters Into A Patent Licensing Agreement To Market And Sell Photovoltaic Technology On Amazon

Biotech

General

GTBP

GT Biopharma Announces Partnership With University Of Minnesota For Phase 1 Clinical Trial Of GTB-3650 Tri-Specific Killer Engager For High-Risk MDS, Refractory/Relapsed AML, And Minimal Residual Disease; University To Sponsor IND Application.

WIIM

BRZE

Braze shares are trading higher following a report suggesting the company could be a target for an acquisition.

RBC Capital analyst Andrew Wong maintains Cameco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCO#TSX">CCO</a>) with a Outperform and raises the price target from C$75 to C$90.

TSX:CCO

RBC Capital Maintains Outperform on Cameco, Raises Price Target to C$90

Geopolitical tensions between Russia and Ukraine are once again roiling global energy markets, with rising prices raising concerns over the potential economic impact <a href="https://www.benzinga.com/topic/inflation">on U.S. consumer bills.</a> 
On Thursday, Russia launched an intercontinental ballistic missile (ICBM) from the Astrakhan region during an overnight strike on Dnipro, Ukraine, Reuters reported, citing the Ukrainian air force. 
As reported by Reuters, security experts said this marks the first use of an ICBM in a military conflict. The missiles are designed for nuclear warhead delivery. There is no indication the missile was nuclear-armed, Reuters said. 
Western officials disagree with Ukraine&#8217;s assessment, The New York Times <a href="https://www.nytimes.com/2024/11/21/world/europe/russia-ballistic-missile-ukraine-war.html">said in a report</a>, and say the missile was likely of intermediate range. The Times said the officials spoke anonymously in order to discuss a private Western intelligence assessment. 
The Ukrainian air force said the missile was fired from over 435 miles away, targeting the central-eastern city of Dnipro. 
While the attack caused injuries to two people, the extent of the damage remains unclear. Ukrainian president Volodymyr Zelenskyy condemned the move, commenting on X: &#8220;Our insane neighbour has once again revealed its true nature.&#8221;
The move adds to escalating tensions, coming on the heels of Ukraine firing two Western-made missiles at Russia on Tuesday and Wednesday, after receiving approval from the White House <a href="https://www.benzinga.com/news/global/24/11/42064198/putin-revises-nuclear-doctrine-for-broader-strikes-after-us-backed-ukrainian-attack-markets-drop-bonds-gain">to target Russian territory.</a>
<h3 class="wp-block-heading">US Natural Gas Prices Spike, Eye Best Monthly Performance Since July 2022</h3>
In the wake of these heightened external geopolitical risks, U.S. natural gas prices surged. 
Futures tied to the Henry Hub benchmark – as tracked by the United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – jumped more than 6% on Thursday, reaching $3.40 per million British thermal units — the highest level since early November 2023.
The commodity is now up 50% for November, positioning itself for its strongest monthly rally since July 2022.
Natural gas demand in the U.S. has been driven by plummeting temperatures, intensifying the need for heating. 
The National Oceanic and Atmospheric Administration warned on Thursday of the season&#8217;s first significant snowfall in the central and northern Appalachians, with heavy accumulation expected through Friday.
&#8220;Higher elevations will have the best chance of significant accumulations, however even the lower elevations of central and northern Pennsylvania and south central New York will likely see some accumulation of snow,&#8221; the NOAA wrote in a post on X.
The U.S. Energy Information Administration is set to release weekly natural gas inventory change later Thursday.
Europe's natural gas market is grappling with fresh supply concerns as winter approaches after Austria&#8217;s OMV Group disclosed over the weekend that it will no longer receive volumes from its long-term contract with Russia's Gazprom.
<h3 class="wp-block-heading">WTI Oil Prices Climb, Gold Eyes 4th Straight Positive Day</h3>
The ripple effects of escalating geopolitical tensions also extended to crude oil markets. 
West Texas Intermediate crude futures, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), climbed 2.2% on Thursday morning, trading at $70 per barrel — the highest level since Nov. 11.
Gold continued to attract demand for safe-haven assets, with the precious metal rising 0.6% to $2,665 per ounce, eyeing the fourth straight session of gains. 
Bitcoin rose 3%, hitting a new peak of $98,367.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097545/feds-bowman-warns-on-inflation-risks-signals-neutral-rate-may-be-closer">Fed&#8217;s Bowman Warns On Inflation, Says Neutral Interest Rates May Be Closer &#8216;Than We Currently Think&#8217;</a></li>
</ul>

Specialty ETFs

Commodities

Global

Economics

Natural Gas Prices Spike To Over 1-Year Highs, Oil Surges To $70 As Ukraine Says Intercontinental Ballistic Missile Fired By Russia

Janney Montgomery Scott analyst Robert Farnam downgrades Hanover Insurance Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) from Buy to Neutral and announces $176 price target.

Downgrades

Janney Montgomery Scott Downgrades Hanover Insurance Gr to Neutral, Announces $176 Price Target

RBC Capital analyst Irene Nattel reiterates Metro (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRU#TSX">MRU</a>) with a Sector Perform and maintains C$90 price target.

Reiteration

TSX:MRU

RBC Capital Reiterates Sector Perform on Metro, Maintains C$90 Price Target

SRAD

Sportradar shares are trading higher after the company announced a multiyear agreement with MLB to provide sports performance analysis of prospects using its Synergy Coaching and Scouting solution.

Hewlett Packard Enterprise Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) disclosed a contract from renewable energy company, RWE AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RWEOY#OTC">RWEOY</a>), to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42105671/rwe-to-harness-ai-driven-weather-modelling-with-hpe-private-cloud-ai" rel="noreferrer noopener">enhance weather data analysis</a>.
RWE has adopted HPE Private Cloud AI, part of the NVIDIA AI Computing by HPE portfolio, to streamline weather model data processing and enhance information retrieval with retrieval-augmented generation (RAG).
The on-premise solution allows RWE&#8217;s researchers to rapidly deploy private cloud AI infrastructure within policy frameworks, enabling quicker experimentation and scaling of AI projects across various domains and regions.
HPE Private Cloud AI, co-developed with NVIDIA and delivered via the HPE GreenLake cloud, offers RWE a streamlined platform for infrastructure management, process automation, and workload orchestration, including sustainability metrics.
This allows RWE&#8217;s research team to focus on model development, accelerating time-to-market and providing a competitive edge in the renewable energy sector.
Fidelma Russo, EVP &amp; GM, Hybrid Cloud &amp; CTO at HPE, said, &#8220;The ability to fine tune and inference AI-driven weather models will be a key enabler to unlock higher efficiencies for RWE&#8217;s renewable energy portfolio and will give them a significant competitive advantage in the market.&#8221;
&#8220;HPE Private Cloud AI is a unique turnkey solution that enables RWE&#8217;s researchers to reach the market quicker and handle massive datasets.&#8221;
Yesterday, Deloitte expanded its collaboration with HPE to implement the newly launched HPE Private Cloud AI with NVIDIA, enhancing its AI capabilities and accelerating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42085548/deloitte-and-hewlett-packard-enterprise-collaborate-to-deliver-private-cloud-ai-capabilities" rel="noreferrer noopener">deployment of Generative AI solutions</a>.
Investors can gain exposure to the stock via&nbsp;First Trust S&amp;P 500 Diversified Dividend Aristocrats ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNGZ#NASDAQ">KNGZ</a>) and Roundhill Generative AI &amp; Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHAT#NYSE">CHAT</a>).
Price Action: HPE shares are up 0.99% at $21.39 premarket at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42105704" target="_blank" rel="noreferrer noopener">SpaceX CEO Elon Musk Reveals Technical Glitch That Led Company To Drop Key Objective Of Starship&#8217;s 6th Test Flight</a></li>
</ul>

Large Cap

CHAT

KNGZ

Rwe Ag Ord Bearer Dm5 American Depository Receipt

RWEOY

HPE Powers RWE's Renewable Energy with AI Weather Modeling

RBC Capital analyst Andrew Wong maintains NexGen Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/NXE#TSX">NXE</a>) with a Outperform and raises the price target from C$10 to C$15.

TSX:NXE

RBC Capital Maintains Outperform on NexGen Energy, Raises Price Target to C$15

ROAD

Construction Partners shares are trading higher after the company raised its FY25 revenue guidance.

Addentax Group Corp. ("Addentax" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>), an integrated service provider focusing on garment manufacturing, logistics services, property management, and subleasing, has announced the signing of a Memorandum of Understanding (MOU) for nationwide strategic cooperation with Shenzhen Yingbin Brand Development Co., Ltd. ("Yingbin Brand"), a prominent brand management company headquartered in Guangdong.

ATXG

Addentax Group Corp. Announces Signing Of MOU For Strategic Cooperation With Shenzhen Yingbin Brand Development Co., Ltd., Offering A Wide Range Of Services In Brand Supply Chain Management, Product Supply Chain Solutions, And Marketing Supply Chain Strategies

Maximus shares are trading lower after the company on Wednesday reported worse-than-expected Q4 adjusted EPS results.

iQIYI shares are trading lower despite a Q3 earnings beat.

RBC Capital analyst Pammi Bir maintains Riocan REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REI#TSX">REI</a>) with a Outperform and raises the price target from C$21 to C$22.

TSX:REI

TSX:REI/UN

RBC Capital Maintains Outperform on Riocan REIT, Raises Price Target to C$22

On Wednesday, Pyxis Oncology, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYXS#NASDAQ">PYXS</a>) released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42099028/pyxis-oncology-announces-favorable-preliminary-pyx-201-clinical-phase-1-part-1-data" rel="noreferrer noopener">multiple solid tumors</a>.
Among evaluable Head and Neck Squamous Cell Carcinoma (HNSCC) patients treated at an identified dose range of PYX-201 from 3.6 – 5.4 mg/kg (n=6), a confirmed 50% objective response rate (ORR) was observed, including one confirmed complete response (CR) and two confirmed partial responses (PR).
The company additionally announced a Clinical Trial Collaboration Agreement with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) for a Pyxis Oncology-sponsored study of PYX-201 in combination with Merck&#8217;s Keytruda (pembrolizumab) in patients with 1L and 2L HNSCC, HR+/HER2- breast cancer, and triple-negative breast cancer (TNBC) and sarcoma.
<ul>
<li>PYX-201 and Keytruda combination dose escalation and expansion study in 1L and 2L HNSCC with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the second half of 2025.</li>
<li>PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced, with preliminary clinical data readout expected in the first half of 2026.</li>
</ul>
Exploratory PYX-201 Phase 1 monotherapy expansion cohorts are planned for ovarian cancer, NSCLC, HR+/HER2 breast cancer, TNBC, and sarcoma. Preliminary clinical data are expected in the second half of 2025.
<ul>
<li>The company also expects to initiate the PYX-201 and Keytruda combination study in HR+/HER2 breast cancer, TNBC, and sarcoma, with preliminary clinical data expected in the second half of 2025 and the first half of 2026.</li>
<li>Preclinical studies of PYX-201 combined with other agents in ovarian cancer and NSCLC will commence in 2025, followed by clinical studies with preliminary clinical data expected in 2026.</li>
</ul>
PYX-201 demonstrated favorable preliminary tolerability profile data with low incidence of dose discontinuation, interruptions, or delays due to treatment-related adverse events.
William Blair analysts note that PYX-201 shows limited effectiveness outside of head-and-neck cancer, with only 8.7% of patients (2 out of 23) responding to tolerable doses of 3.6 mg/kg, 4.4 mg/kg, and 5.4 mg/kg.
&#8220;At this point, we are unsure whether the three unconfirmed responses could ultimately be confirmed,&#8221; the analysts writes.
The analysts has reduced the probability of success for PYX-201 to 10% from 35%. The updated fair value stands at $250 million or roughly $4.25 per share, comprising $1.77 per share from PYX-201 and $2.48 per share of cash.
With no major stock-moving events expected until the second half of 2025, the analysts estimate the stock will trade around $2.80 per share soon. William Blair says it includes $1.77 per share for PYX-201 and $1.07 for remaining cash by late 2025.
William Blair downgrades <a target="_blank" href="https://www.benzinga.com/quote/PYXS/analyst-ratings" rel="noreferrer noopener">Pyxis to Market Perform</a>, saying, &#8220;Since we view the head-and-neck cancer results as difficult to differentiate, coupled with modest activity in other solid tumor histologies.&#8221;
Price Action: PYXS stock is down 42.15% to $2.21 during premarket trading on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42098028/qualcomms-shift-from-handsets-to-ai-and-automotive-wins-analysts-confidence" target="_blank" rel="noreferrer noopener">Qualcomm&#8217;s Shift From Handsets To AI And Automotive Wins Analysts&#8217; Confidence</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Health Care

Movers

Trading Ideas

PYXS

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

SWVL

Swvl Signs Three-Year Contract With G4S In Saudi Arabia To Provide SaaS-Based Mobility Solutions, Enhancing Fleet Efficiency Across Riyadh, Jeddah, And Dammam With Over 14,000 Monthly Trips; Financial Terms Not Disclosed

Reports Q3 revenue ex-items $44M, consensus $45M. "I'm extremely proud of the significant progress we made in the third quarter," said Jason Kelly,...

Gingko Bioworks reports Q3 EPS ($1.08), consensus ($2.72)

Previous view $170M-$190M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the ...

Gingko Bioworks raises FY24 revenue view to $215M-$235M, consensus $185.52M

The latest update is out from Ginkgo Bioworks Holdings ( ($DNA) ). Ginkgo Bioworks reported a significant revenue increase of 61% in Q3 2024, prima...

Ginkgo Bioworks Reports 61% Revenue Jump in Q3 2024

Check out this evening's top movers from around Wall Street, compiled by The Fly.&nbsp;&nbsp; HIGHER AFTER EARNINGS – Dave (DAVE)&nbsp;up 33.5% Cav...

Closing Bell Movers: Instacart down 6% after earnings

Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Transcript

TD Cowen analyst Brendan Smith maintained a Buy rating on Ginkgo Bioworks Holdings (DNA – Research Report) today and set a price target of $10.00. ...

Positive Outlook for Ginkgo Bioworks: Strategic Developments and Financial Strength Bolster Buy Rating

Ginkgo Bioworks: Not Enough Progress

BTIG analyst Mark Massaro lowered the firm's price target on Ginkgo Bioworks (DNA) to $6 from $7 and keeps a Sell rating on the shares after its Q3...

Ginkgo Bioworks price target lowered to $6 from $7 at BTIG

Ginkgo Bioworks: Unproven Transition But 2025 Is Looking Better

In a report released yesterday, Tejas Savant from Morgan Stanley maintained a Hold rating on Ginkgo Bioworks Holdings (DNA – Research Report), with...

Ginkgo Bioworks Holdings: Hold Rating Amidst Revenue Growth and Restructuring Efforts

CART

CAVA

DAVE

DNABW

FLUT

GDYN

GRPN

HNST

INSG

MARA

MODG

NTRA

PGNY

RIVN

SAVE

SOUN

SPOT

SWKS

Legal

Press Releases

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

Ginkgo Regains Compliance with NYSE Minimum Bid Price Requirement

Ginkgo Bioworks Launches New Protein LLM and Model API Built on Google Cloud Technology

Ginkgo Bioworks Launches Ginkgo Datapoints to Transform AI Model Training in Biology

Pomerantz LLP Announces that this is a Reminder of a Proposed Class Action Settlement on Behalf of Purchasers of Ginkgo Bioworks Holdings, Inc. Common Stock - DNA

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Finding Family DNA Podcast Series Wins Gold!

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Earnings

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Alto Ingredients

ASP Isotopes

Aspen Aerogels

Bon Natural Life Limited - Ordinary Shares

Bon Natural Life

Danimer Scientific

Ecovyst

Flexible Solutions International Inc. Common Stock (CDA)

Flexible Solutions Intl

Flotek Industries

Innospec

Quaker Houghton

Minerals Technologies

Ingevity

Northern Technologies International Corporation - Common Stock

Northern Technologies

Perimeter Solutions

Rayonier Advanced Materials Inc. Common Stock

Rayonier Adv Materials

Stepan

Sensient Technologies Corporation Common Stock

Sensient Technologies

Valhi

TD Cowen

BTIG

Goldman Sachs

Morgan Stanley

Genentech

수요일에 캐시 우드가 이끄는 아크 인베스트(Ark Invest)는 이 회사의 인상적인 2분기 납품 실적에 힘입은 최근 상승세에도 불구하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)의 상당 수의 주식을 매각하여 주목할만한 움직임을 보였다.
테슬라 주식
아크 인베스트는 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 통해 테슬라 지분을 줄여 13,213주를 매각했다. 이번 거래는 테슬라의 주가가 최근 화요일에 10.20% 급등해 4월 말 이후 최고의 장중 거래를 기록했다는 점을 감안하면 놀라운 일이었다. 특히 화요일에 아크 인베스트는 <a href="https://www.benzinga.com/markets/equities/24/07/39611275/cathie-woods-ark-invest-sells-tesla-shares-worth-14-5m-amid-rally-driven-by-q2-delivery-numbers-">1,450만 달러</a> 상당의 테슬라 주식을 매각했다.
이러한 상승은 주로 일론 머스크가 이끄는 이 회사의 <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">2분기 실적</a>에 의해 주도되었다. 테슬라는 예상 차량 439,000대를 크게 초과하는 443,956대를 인도했다고 보고했다. 이러한 놀라운 상승세는 랠리를 촉진하여 주가를 2024년 최고치로 끌어올렸다. 판매의 대부분은 저렴한 모델 3 및 Y에서 이루어졌으며, 더 비싼 모델 X, S 및 신형 사이버트럭에서는 21,551대만 판매되었다.
최종 종가 246.39달러를 기준으로 수요일에 판매된 주식의 가치는 약 325만 달러에 달한다. 이날 테슬라 주가는 6.5% 급등했다.
기타 중요한 거래:
<ul>
<li>아크 인베스트의 ARKF 펀드는 텔레닥(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 팔았다.</li>
<li>ARKG 펀드는 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 2,551주 매수하고, 버브 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>)의 주를 팔았다.</li>
<li>ARKK 펀드는 아처 에비에이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NASDAQ">ACHR</a>)의 주를 사고, 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주를 팔았다.</li>
<li>ARKQ 펀드는 에어로바이런먼트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>)의 주를 팔았다. ARKX 펀드는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)의 주를 샀다.</li>
</ul>
이미지는 셧터스톡을 통해 제공됨
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했다

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 변동성이 큰 시장 속에서 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)와 코인베이스 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)에서 상당한 거래를 했다. 이러한 눈에 띄는 거래는 아크의 다양한 ETF가 수행한 일련의 거래의 일부였다.
로쿠 거래
ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 로쿠에서 127,540주를 매입했다. ARKK 펀드는 106,420주를 인수했고, ARKW 펀드는 21,120주를 추가했다. 이 거래액은 730만 달러에 달했다. 수요일, 로쿠의 주가는 정기 세션에서 4.6% 상승한 57.16달러로 마감했다.
특히 우드의 회사는 <a href="https://www.benzinga.com/markets/equities/24/06/39493817/cathie-wood-led-ark-invest-dumps-4-3m-worth-of-nvidia-shares-amid-rebound-swoops-into-buy-stock-">하루 전</a>에 530만 달러 상당의 로쿠 주식을 구매했다. 이러한 움직임은 <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats" target="_blank" rel="noopener">치열한 강세와 약세 논쟁</a> 사이에 주식이 갇힌 로쿠의 격동적인 시장 움직임 속에서 이루어졌다.
TV 스트리밍 플랫폼이자 넷플릭스와 같은 스트리밍 플랫폼의 경쟁사인 로쿠는 <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday">최근</a> 광고 인벤토리와 광고주 수요를 직접 연결하는 광고 기술 솔루션인 로쿠 익스체인지(Roku Exchange)를 출시했다.
코인베이스 거래
아크 인베스트의 ARKW ETF는 703,393달러 상당의 코인베이스 주식 3,278주를 매각했다. 이번 판매는 미국 정부와 연결되어 있는 것으로 여겨지는 지갑을 통해 상당한 규모의 암호화폐가 코인베이스로 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39511595/uncle-sam-on-the-move-us-government-transfers-millions-in-bitcoin-to-coinbase" target="_blank" rel="noopener">이전</a>된 데 따른 것이다. 미국 정부는 2억 4,100만 달러 상당의 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ​​3,940개를 코인베이스로 이전했다.
미국 정부의 이러한 움직임으로 인해 암호화폐 시장이 <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39516076/bitcoin-ethereum-dogecoin-retrace-on-fears-of-240m-sale-by-us-government-king-crypto-shoul">하락</a>했다. 비트코인은 이전 거래 세션에서 62,000달러로 약간 반등한 후 61,000달러 아래로 떨어졌다.
그 외 핵심 거래들:
<ul>
<li>아크 인베스트의 ARKG ETF는 깅코 바이오웍스 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NYSE">DNA</a>)의 주식을 팔고 10X 지노믹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)의 주식을 샀다.</li>
<li>ARKG 펀드는 텔레닥 헬스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>)의 주식을 매도하고 인텔리아 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>)의 주식을 샀다.</li>
</ul>
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>가 작성하고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집한 바 있다.

2024년 6월 25일 화요일, 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 상당한 시장 변동성 속에서 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 로쿠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)에서 상당한 거래를 했다. 이러한 거래는 아크의 다양한 ETF가 이행한 일련의 거래의 일부였다.
엔비디아 거래
이 회사의 ARK 자율 기술 및 로봇공학 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)는 화요일에 엔비디아 주식 33,834주를 매각했다. 거래 규모는 430만 달러에 이른다. 이날 엔비디아 주가는 6.8% 오른 126.09달러로 마감했다.
이러한 움직임은 목요일 이후 <a href="https://www.benzinga.com/top-stories/24/06/39490865/nvidia-rebounds-over-6-after-550b-market-cap-loss">5500억 달러</a>의 감소를 보인 이 기술 대기업의 상당한 시가총액 손실에 따른 것이다. 그럼에도 불구하고 엔비디아는 화요일에 6% 이상 반등하여 마이크로소프트와 애플에 이어 세 번째로 가치 있는 기업으로서의 위치를 ​​되찾았다.
S&amp;P 500 지수에 대한 엔비디아의 영향력에 대한 우려가 제기되었으며, 일부 분석가들은 이 회사가 상당한 매도세를 겪을 경우 잠재적인 시장 침체가 더욱 확대될 수 있다고 <a href="https://www.benzinga.com/trading-ideas/technicals/24/06/39482710/nvidia-stock-drops-over-12-in-3-trading-days-indicators-suggest-whats-next">경고</a>했다. 이러한 우려에도 불구하고 엔비디아의 펀더멘털은 여전히 ​​강력하며, 데이터 센터와 자동차 부문의 강력한 성과에 힘입어 2024년 1분기 실적이 월스트리트의 기대치를 뛰어넘었다.
로쿠 거래
ARK 혁신 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)와 ARK 차세대 인터넷 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>)는 화요일에 530만 달러 상당의 거래를 통해 로쿠의 주식 96,465주를 매입했다. 로쿠의 주가는 화요일 정규 세션에서 0.35% 상승한 54.64달러로 마감했다.
이러한 움직임은 최근 로쿠의 주가가 <a href="https://www.benzinga.com/general/entertainment/24/06/39422115/roku-stocks-wild-ride-bullish-analysts-bet-on-growth-despite-competitive-threats">강한 매수-매도 논쟁</a>에 휘말리면서 로쿠의 격동적인 시장 상황 속에서 이루어졌다. 경쟁적 위협에도 불구하고 낙관적인 투자자들은 여러 측면에서 로쿠의 수익 잠재력에 열광하고 있다.
로쿠의 라이벌인 넷플릭스는 최근 광고 인벤토리와 광고주 수요를 직접 연결하도록 설계된 <a href="https://www.benzinga.com/markets/equities/24/06/39295418/whats-going-on-with-tv-streaming-platform-rokus-shares-on-wednesday" target="_blank" rel="noopener">광고 기술 솔루션</a>인 로쿠 익스체인지(Roku Exchange)를 공개했다. 이 플랫폼은 스트리밍 우선 광고 기술의 상당한 발전을 나타내며 시장에서 로쿠의 입지를 더욱 공고히 한다.
기타 주요 거래:
<ul>
<li>아크 인베스트의 ARKG펀드가 깅코 바이오웍스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NASDAQ">DNA</a>)의 상당량의 주식을 매도했다. ARKG는 또한 아크투루스 테라퓨틱스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>)와 10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>)의 주식을 매수했다.</li>
<li>ARKK 펀드는 줌 비디오 커뮤니케이션즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZM#NASDAQ">ZM</a>) 주식을 매도했으며, 페이저듀티(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) 주식을 매수했다. ARKQ는 블레이드 에어 모빌리티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>)와 마크포지드 홀딩(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKFG#NASDAQ">MKFG</a>)의 주식을 매수했다.</li>
</ul>
본 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 통해 작성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>이 편집했습니다.

깅코 바이오웍스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NASDAQ">DNA</a>)는 목요일 시장 마감 후 1분기 실적을 발표했다. 이 보고서의 <a href="https://www.benzinga.com/pressreleases/24/05/n38743006/ginkgo-bioworks-reports-first-quarter-2024-financial-results">주요 내용을 살펴보자.</a>
세부 내용 (The Details):
깅코 바이오웍스는 분기별 매출 3,800만 달러를 보고했는데, 이는 분석가 합의 추정치인 4,604만 4,000달러를 17.47% 미달했고, 전년 대비 매출은 52.91% 감소한 수치이다. 이 회사는 매출 감소가 주로 깅코의 바이오보안 부문에서 K-12 테스트 축소로 인해 발생했다고 밝혔다.
깅코는 셀 엔지니어링(Cell Engineering)의 해당 분기 매출이 2,800만 달러였으며 이는 초기 단계 고객의 매출 감소가 대규모/기업 고객의 성장으로 부분적으로 상쇄되면서 18% 감소했다고 밝혔다. 바이오보안 매출은 1,000만 달러였으며 총 이익 마진은 8%였으며 이는 보다 반복적인 비즈니스 모델로의 전환 초기 단계를 반영한다고 이 회사가 말했다.
깅코의 CEO인 제이슨 켈리(Jason Kelly)는 &#8220;깅코는 생명공학 생태계에서 점점 더 중요한 부분을 차지하고 있으며, 우리는 이를 유지하기 위해 단호한 조치를 취하고 있다&#8221;고 말했다. "우리는 공통 플랫폼에서 수많은 다양한 프로그램을 제공할 수 있다는 것을 입증했지만 1분기 매출은 실망스럽다. 이러한 추세는 바뀌어야 하며, 우리는 고객에게 판매하는 제품과 깅코에서 매출을 창출하는 업무 수행 방식을 단순화하고 있다."
이 회사는 연간 실행률 기준으로 2026년 말까지 조정 EBITDA 손익분기점을 달성하겠다는 계획을 발표했다. 이 계획에는 물리적 공간 및 관련 비용을 최대 60%까지 줄이고 인력을 줄여 인건비를 최소 25% 절감하는 것이 포함된다.
관련 뉴스: <a href="https://www.benzinga.com/news/24/05/38741220/whats-going-on-with-pelotons-stock">펠로톤의 주식에 대해 어떤 일이 일어나고 있나요?</a>
DNA 주가 행동: <a href="https://www.benzinga.com/news/24/05/38741220/whats-going-on-with-pelotons-stock">Benzinga Pro</a>에 따르면 깅코의 주식은 목요일 시간외 거래에서 10.88% 하락한 82센트에 거래되었다.
이미지:Pixabay의 Gerd Altmann

After-Hours Center

깅코 바이웍스: 실망스러운 1분기 매출로 주가 급락

Comments

Ginkgo Bioworks Holdings

뉴스

에 대한 최신 뉴스 Ginkgo Bioworks Holdings (NYSE:DNA) 주식

목요일, 7월 04, 2024

목요일, 6월 27, 2024

수요일, 6월 26, 2024

목요일, 5월 09, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌